Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VirbacVRBCF 80 EV-to-OCF is 14.84 as of Aug. 04, 2026, which is 14% below its 10-year median of 17.24. GuruFocus rates VRBCF with a GF Score™ of 80/100 and a GF Value™ of $352.03 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Virbac ranks worse than 59.62% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Virbac's Enterprise Value is $3,451 Mil.
Virbac's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $233 Mil. Therefore, Virbac's EV-to-OCF for today is 14.84.
The historical rank and industry rank for Virbac's EV-to-OCF or its related term are showing as below:
VRBCF'
s EV-to-OCF Range Over the Past 10 Years
Min: 10.3 Med: 17.24 Max: 49.19
Current: 14.82
During the past 13 years, the highest EV-to-OCF of Virbac was 49.19. The lowest was 10.30. And the median was 17.24.
VRBCF's EV-to-OCF is ranked worse than 59.62% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs VRBCF: 14.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-04), Virbac's stock price is $383.25.
Virbac's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $20.905. Therefore, Virbac's PE Ratio (TTM) for today is 18.33.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virbac's share price for today is $383.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virbac's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $20.905.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Virbac EV-to-OCF Related Terms
Virbac EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Virbac's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Virbac's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Virbac's EV-to-OCF falls into.
Virbac's current Enterprise Value is $3,451 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virbac's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $233 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virbac (VRBCF) has a EV-to-OCF of 14.84 as of Aug. 04, 2026. This is 14% below median its historical median of 17.24. Over the past decade, Virbac's EV-to-OCF has ranged from 10.30 to 49.19. According to the industry distribution chart, Virbac ranks #601 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 59.6%.
Is Virbac's EV-to-OCF too high?
Virbac's current EV-to-OCF of 14.84 is 14% below median its 10-year median of 17.24. Over the past 10 years, this metric has ranged from a low of 10.30 to a high of 49.19. The Drug Manufacturers industry median EV-to-OCF is 10.83. Virbac's value of 14.84 is 37.1% above this industry median. Based on the distribution chart, Virbac ranks #601 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Virbac has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #601 out of 1008 companies for EV-to-OCF. This places Virbac in the lower half of its industry. The industry median EV-to-OCF is 10.83. Virbac's value of 14.84 is 37.1% above this benchmark. Historically, Virbac's own EV-to-OCF has ranged from 10.30 to 49.19 over the past decade. While the company's 10-year median is 17.24 vs. the industry median of 10.83, Virbac has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current EV-to-OCF of 14.84 is 37.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current EV-to-OCF is 14.84, which is 14% below median its own 10-year median of 17.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (VRBCF) is currently considered Fairly Valued. The stock's GF Value™ is $352.03, compared to a current price of $383.25 — trading 8.9% above its estimated fair value. The current EV-to-OCF is 14.84, which is 14% below median its 10-year median of 17.24 and 37.1% above the Drug Manufacturers industry median of 10.83. Virbac's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Virbac (VRBCF), the current EV-to-OCF is 14.84 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (VRBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be overvalued.
The current stock price of $383.25 is trading 8.9% above its estimated GF Value™ of $352.03.
GuruFocus considers Virbac to be Fairly Valued.
Key valuation signals for VRBCF:
EV-to-OCF: 14.84 (14% below median its 10-year median of 17.24)
GF Value™: $352.03 vs. price of $383.25 (8.9% above fair value)
Industry Position: 37.1% above the Drug Manufacturers median (#601 of 1008)
No single metric tells the full story. See the VRBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
80GF Score
Get the complete analysis for VRBCF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRBCF has been successfully added to your 
